FDA accepts cemdisiran for review to treat generalized myasthenia gravis

Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by the FDA and the European Medicines Agency, according to officials with Regeneron Pharmaceuticals. If approved, cemdisiran would be the first small interfering RNA (siRNA) treatment for generalized myasthenia gravis, a chronic autoimmune disorder, and the only therapy to be